Google
SGHT Stock Analysis — SIGHT SCIENCES INC (Healthcare >> Medical Devices)
SGHT FAQ
What is SGHT's ROE?
SIGHT SCIENCES INC reports a Return on Equity (ROE) of -69.11%.
What is SGHT's dividend yield?
SIGHT SCIENCES INC offers a dividend yield of 0.00%.
What is SGHT's Quality Score?
Our AI rates SGHT's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy SGHT?
Our AI Timing Score for SGHT is 89 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does SGHT belong to?
SIGHT SCIENCES INC is classified under the Healthcare >> Medical Devices sector on the NASDAQ exchange
SGHT AI Analysis Summary
Our AI summary for SGHT: SIGHT SCIENCES INC (NASDAQ), Healthcare >> Medical Devices sector. The stock currently trades at a P/E of 0.00, ROE of -69.11%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 89/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 5.26
Price
0.00
(0.00%)
Day Change
|
|
|---|
SGHT, the overall quality is not good ( Quality = 31) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROE is decreasing significantly
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 5.26 |
| PBV / Sector |
5.31 / -101.57
|
| Earning Per Share | -0.68 |
| PE / Sector |
N/A / 31.23
|
| PEG or PE/Growth / Sector |
N/A / 0.40
|
| Average 1M Daily Value |
0.78 M
GREAT
|
| Average 1W Daily Value |
0.53 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
56% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-01 08:00:28 |
| Symbol | SGHT |
| Name | SIGHT SCIENCES INC |
| Sector | Healthcare >> Medical Devices |
| Market | NASDAQ |
| Listed Shares | 54.41 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 286.20 / 20,104.97 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 4040 Campbell Avenue, Menlo Park, CA, United States, 94025
Phone: 877 266 1144
Website: https://www.sightsciences.com
Employees: 186
Sector: Healthcare >> Medical Devices
Description: Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye. It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and OMNI EDGE, an implant-free and minimally invasive glaucoma surgery technology. The company also provides SION, a bladeless and manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork; and TearCare system, a proprietary, interventional, dry eye device designed to melt and facilitate the comprehensive removal of meibomian gland obstructions and restore gland functionality and healthy oil production for adult patients with evaporative dry eye disease due to meibomian gland disease when used in conjunction with manual expression of the meibomian glands for ophthalmologists and optometrists. It serves hospitals, medical centers, and eyecare professionals through sales representatives and distributors. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Medical Devices
Click a bubble to view stock details · Bubble size represents market capitalization share
